HYCOR Appoints New Chief Financial Officer
GARDEN GROVE, Calif., Jan. 8, 2013
GARDEN GROVE, Calif., Jan. 8, 2013 /PRNewswire/ -- HYCOR Biomedical, Inc., a
leading manufacturer and marketer of in vitro diagnostic products for the
global allergy, autoimmune and urinalysis markets, today announced that Ed
Cordell has joined the company as Chief Financial Officer.
"Ed's three decade career brings a set of invaluable skills that we need as we
embark on our next phase of growth," said Dick Aderman, CEO, HYCOR. "His
tested financial and strategy expertise will help ensure HYCOR remains on a
strong path to meet our customer and investors expectations. We welcome Ed and
are thrilled to have such a high caliber executive join our team."
Cordell is a seasoned financial executive with more than 30 years of
experience and a proven record of success. He joins HYCOR from Given Imaging,
Inc., a world leader in GI medical devices and pioneer of capsule endoscopy,
where he was Chief Financial Officer with responsibility for the North and
South American regions. Cordell brings extensive expertise in operational,
accounting and financial challenges of building high-growth and high-tech
businesses with a majority of focus on medical device companies.
Cordell has also held senior financial executive positions with Gravograph,
the world's leading maker and seller of machines, accessories and materials
used in the engraving industry, Novoste Corporation, who was the first company
to develop and market a radiation therapy system to treat restenosis and
CryoLife, a producer of implantable living human tissues and surgical
adhesives. Cordell received his Bachelor of Science degree from the University
"I'm very excited to join HYCOR during this crucial time as the company moves
to expand the business," said Cordell. "I look forward to joining a superb
leadership team and working with them to support the continued growth."
About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro
diagnostics products. Since its founding, HYCOR has expanded its presence into
urinalysis, allergy and autoimmune products used in clinical laboratories,
hospitals and doctors' offices worldwide. Among its products, HYCOR markets
the HYTEC™, KOVA^® and AUTOSTAT™ brands. The company is focused on delivering
products that provide the highest value to clinicians through innovation,
reliability and customer service. For more information, please visit
About Linden, LLC
Linden is a Chicago-based private equity firm focused exclusively on leveraged
buyouts in the healthcare and life science industries. Linden's strategy is
based upon three elements: i) healthcare and life science industry
specialization, ii) integrated private equity and operating expertise, and
iii) strategic relationships with large corporations. Linden's portfolio
includes BarrierSafe Solutions International, Behavioral Centers of America,
Corpak MedSystems, Drayer Physical Therapy Institute, HYCOR Biomedical, and
Ranir. For additional information, please visit www.lindenllc.com.
SOURCE HYCOR Biomedical, Inc.
Contact: Katherine Dral, +1-310-309-1029, Kdral@ccapr.com
Press spacebar to pause and continue. Press esc to stop.